

progressing despite prior therapy with at least anthracyclines (A) and ifosfamide (I). Primary endpoint was time to progression (TTP) assessed by independent review; response rate (RR), progression-free (PFS) and overall survival were secondary endpoints. In the protocol-specified primary analysis, TTP ($p=0.030$; HR 0.73) and PFS ($p=0.042$; HR 0.75) were significantly better with the q3wk 24h T schedule, in spite of a modest 5.6% (12% per investigators) RR by RECIST. Acknowledging the limitations of RR by RECIST as a surrogate for clinical benefit in sarcomas, 3 supportive analyses were conducted: Clinical Benefit Rate (CBR), Growth Modulation Index (GMI) and Maximum % of Tumour Variation (MTV).

Methods: CBR was defined as the sum of CR+PR+SD/24 wks. MTV was calculated as: (minimum sum of longest diameters [SLD] of all lesions before or at PD date – SLD at baseline)/(SLD at baseline)-100 (212 pts evaluable). GMI (inpatient-specific historical control) was calculated as: TTP with T / TTP with prior chemo for advanced/metastatic sarcoma (218 pts evaluable; data prospectively collected). A GMI >1.33 (TTP with T $\geq 33\%$ prior TTP) was judged as indicative of pt benefit.

Results: CBR and MTV were significantly better with the q3wk 24h T schedule. CBRs of 39% and 24% were achieved with the q3wk 24h and qwk 3h schedules (Fisher's; $p=0.022$). MTV showed tumour shrinkage in target lesions in 51% pts in the q3wk 24h arm vs 32% in the qwk 3h arm (Mann-Whitney-Wilcoxon; $p=0.0008$). Most pts (67%) had bulky tumours at study entry. GMI >1.33 was achieved in 37% (q3wk 24h) and 31% (qwk 3h) of pts. Last prior chemo was A+I in 48% of pts, gemcitabine-based regime (17%), single-agent I (13%) and others.

Conclusions: The outcomes with the less efficacious qwk 3h arm support this T schedule as an active control. However, consistently better outcomes were seen with the q3wk 24h T schedule. Overall, these results add biological plausibility to the significantly better outcomes in the primary endpoint TTP seen with T q3wk 24h and provide confidence in the clinical relevance of the overall findings. CBR, GMI and MTV, if adequately applied, appear more useful endpoints than conventional RR per RECIST to detect clinical benefit in pts with advanced/metastatic sarcomas.

7513

POSTER

Impact of local management on long-term outcomes in Ewing's tumor of the pelvis: the University of Florida experience

D.J. Indelicato¹, S.R. Keole¹, A.H. Shahlaee², C.G. Morris³, C.P. Gibbs⁴, M.T. Scarborough⁴, R.B. Marcus⁵. ¹University of Florida, Radiation Oncology, Gainesville Florida, USA; ²University of Florida, Pediatric Oncology, Gainesville Florida, USA; ³University of Florida, Statistics/Radiation Oncology, Gainesville Florida, USA; ⁴University of Florida, Orthopedic Oncology, Gainesville Florida, USA; ⁵Emory University, Radiation Oncology, Atlanta Georgia, USA

Purpose: Comprehensive reports of long-term outcomes are limited but nonetheless crucial to the debate regarding local management of pelvic Ewing's tumor. This retrospective analysis describes our 35-year experience with respect to disease control and functional status.

Patients and Methods: Thirty-five patients with localized Ewing's tumors of the pelvis were treated from 1970–2005. Twenty-six patients were treated with definitive radiotherapy (RT) and 9 patients were treated with combined local therapy in the form of surgery + RT (8 preoperative and 1 postoperative). The median RT dose was 55.2Gy. The patients who received RT alone were more likely to be older males with larger tumors exhibiting soft-tissue extension. All patients received standard chemotherapy. Patients in the definitive RT group were more likely to receive etoposide and ifosfamide or undergo bone marrow transplant. Median potential follow-up was 19.4 years. Functional outcome was assessed using the Toronto Extremity Salvage Score (TESS).

Results: 5-year absolute rates of local control and cause-specific survival in the post-1985 era have increased by 2% and 24% respectively. The 15-year actuarial overall survival, cause-specific survival, freedom from relapse rate, and local control rates were 26% vs. 76% ($p=0.016$), 26% vs. 76% ($p=0.016$), 28% vs. 78% ($p=0.015$), and 64% vs. 100% ($p=0.087$), respectively, for patients treated with definitive RT and combined therapy. Overall, tumors <8 cm had significantly better cause-specific survival but this was unrelated to local control. The median TESS for the definitive RT and combined therapy groups were 99 and 94 respectively ($p=0.19$). Six definitive RT patients (23%) had serious complications including two secondary malignancies, a pathologic fracture, and osteoradionecrosis requiring hip replacement. Bowel perforation was the only serious complication observed in the combined therapy group.

Conclusion: Despite improvement in cause-specific survival over the past 35 years, we have made little progress in terms of local control. A small subset of eligible patients may benefit from complete excision, but rates of disease control and complication are poor when it is necessary to treat Ewing's tumors of the pelvis with RT alone. Most patients have unresectable tumors and therefore innovative RT strategies are needed to improve long-

term disease outcomes and minimize side effects while maintaining an acceptable functional result.

7514

POSTER

Long-lasting St. Jude Hospital protocol in adult Ewing sarcoma patients

A.S. Ataergin¹, A. Ozet¹, F. Arpacı¹, M. Turan², C. Ulutin³, M. Ozturk¹, F. Kilicli¹, B. Ozturk¹, S. Komurcu¹, O. Kuzhan¹. ¹GATA Faculty of Medicine, Medical Oncology and BMT Unit, Ankara, Turkey; ²GATA Faculty of Medicine, Hydroclimatology, Ankara, Turkey; ³GATA Faculty of Medicine, Radiation Oncology, Ankara, Turkey

Background: Adult patients with Ewing sarcoma may achieve long-term survival with local treatment modalities and systemic chemotherapy. Although chemotherapy is effective in this setting, a standard chemotherapy regimen is not yet developed. In this study, the feasibility and the effectiveness of long-term ewing sarcoma protocol of St. Jude Hospital.

Materials and Methods: Twenty-five adult patients with ewing sarcoma (22 males, 3 females) received 41-week St. Jude Hospital protocol. The protocol consisted of induction chemotherapy applied within weeks 0 to 6 (ifosfamide 2 g/m²/day, days 1–3, etoposide 150 mg/m²/day, days 1–3, cyclophosphamide 1.5 g/m² day 5, doxorubicin 45 mg/m² day 5); on the 9th week surgical resection with or without radiotherapy was done, followed by vincristin 1.5 mg/m², D-actinomycin 1.5 mg/m² within weeks 11 and 17 and the maintenance treatment within weeks 20 and 41 (ifosfamide 2 g/m²/day, days 1–5; etoposide 150 mg/m²/day, days 1–5; cyclophosphamide 1/m²/day, days 1 and 2; doxorubicin 60 mg/m² day 1, as continuous infusion in 24 hours). All chemotherapy regimens were given every three weeks.

Results: The median age of the patients was 23 (range: 18–55). The initial stage of the disease was IIB in 20 cases, and IV in 5 cases. In 10 cases tumor was originated from the extremity, and in 14 cases from other bones from the extremities. Fourteen cases underwent surgical resection and 22 cases were given radiotherapy for local control. All cases completed the treatment protocol. The median duration of chemotherapy was 44 weeks (range: 41–56). Twelve cases (48%) achieved complete response, 7 cases (28%) achieved partial response, whereas 5 cases (20%) had progression after the completion of the protocol. Thirteen cases (52%) developed myelotoxicity, 2 cases (0.08%) developed nephrotoxicity, 2 cases (0.08%) developed neurotoxicity, and 3 cases (12%) developed angina pectoris during the treatment protocol. No dose reduction or modification was made in the patients. In 11 patients (44%) G-CSF was used, 13 patients (52%) were given erythrocyte transfusions. 4-year overall survival rates were 43% in stage II patients and 40% in stage IV patients, respectively. 4-year disease-free survival rates were 25% in stage II patients and 20% in stage IV patients, respectively.

Conclusions: In conclusion, the long-lasting St. Jude Hospital protocol was found similar to other chemotherapy protocols in regard to toxicity and survival in adult patients with Ewing sarcoma.

7515

POSTER

Prognostic factors in osteosarcoma. The arguments for risk adapted up-front treatment

G. Machak¹, B. Bokhian¹, N. Kochergina¹, O. Senko², M. Aliev³. ¹N.N. Blokhin Russian Cancer Research Center, general oncology, Moscow, Russian Federation; ²Computer Center of RAS, pattern recognition group, Moscow, Russian Federation; ³N.N. Blokhin Russian Cancer Research Center, general oncology, Moscow, Russian Federation

Background: The response to induction chemotherapy is the standard criteria for risk assessment in osteosarcoma. In order to evaluate the risk earlier, we have investigated several pretreatment tumor related characteristics.

Materials and Methods: The database included 593 patients treated at the N.N. Blokhin Russian Cancer Center. Between 1979 and 1986, preoperative treatment comprised one 72-hour IA infusion of DOX 90 mg/m² and radiotherapy 40 Gy. From 1986 to 1999 induction chemotherapy consisted of 3–5 monthly cycles of IA DOX 90 mg/m² or CDDP 120 mg/m². In both protocols 6 cycles of CAP (cisplatin 100 mg/m² + doxorubicin 60 mg/m² + cyclophosphamide 600 mg/m²) chemotherapy were administered after removal of primary. The last protocol consisted of 3–4 cycles of intensified induction chemotherapy with DOX 90 mg/m² and CDDP 120 mg/m² IV or IA, surgery at week 20 and 6 cycles of adjuvant chemotherapy with DOX, CDDP, IFO (standard dose) and VP-16. Cox regression was used for multivariate analysis.

Results: The following pretreatment factors were predictive for disease-free survival (DFS) in univariate analysis: stage by Enneking ($p < 0.00001$),